Table 1 Demographic tables for the MCED, MRD and monitoring cohorts. MCED samples do not have event status or information related to body mass index. *:Same normal cohort was used for MCED holdout and for MRD/monitoring training.

Patient Age at Diagnosis

Median Age (range), years

58 (23–89)

58 (22–94)

60 (16–96)

60 (34–85)

63 (34–88)

Age < 50, n(%)

240 (23.7)

599 (22.4)

690 (20.1)

24 (26.4)

18 (17.8)

Age 50–59, n(%)

262 (25.9)

828 (31)

928 (27)

22 (24.2)

20 (19.8)

Age 60–69, n(%)

282 (27.8)

833 (31.1)

1027 (29.9)

17 (18.7)

29 (28.7)

Age > = 70, n(%)

125 (12.3)

413 (15.4)

705 (20.5)

23 (25.3)

34 (33.7)

Unknown, n(%)

104 (10.3)

2 (0.1)

89 (2.6)

-

-

Gender

Male, n(%)

516 (50.9)

1047 (39.1)

1167 (33.9)

32 (35.2)

16 (15.8)

Female, n(%)

497 (49.1)

1627 (60.8)

2185 (63.5)

54 (59.3)

85 (84.2)

Unknown, n(%)

-

1 (0)

87 (2.5)

-

-

Stage

I, n(%)

196 (19.3)

284 (10.6)

233 (6.8)

-

-

II, n(%)

137 (13.5)

129 (4.8)

51 (1.5)

28 (30.8)

43 (42.6)

III, n(%)

110 (10.9)

90 (3.4)

70 (2)

45 (49.5)

58 (57.4)

II/III, n(%)

-

-

-

13 (14.3)

-

IV, n(%)

62 (6.1)

23 (0.9)

678 (19.7)

-

-

Normal, n(%)

506 (50)

2149 (80.3)

2149 (62.5)

-

-

Unknown, n(%)

2 (0.2)

-

258 (7.5)

-

-

Cancer Origin Tissue

Bladder, n(%)

29 (2.9)

2 (0.1)

27 (0.8)

-

2 (2)

Brain, n(%)

13 (1.3)

-

-

-

-

Breast, n(%)

1 (0.1)

21 (0.8)

550 (16)

36 (39.6)

43 (42.6)

Cancer of Unknown Primary, n(%)

-

-

27 (0.8)

-

-

Cervical, n(%)

45 (4.4)

11 (0.4)

10 (0.3)

-

-

Cholangiocarcinoma, n(%)

11 (1.1)

18 (0.7)

27 (0.8)

2 (2.2)

-

Colorectal, n(%)

44 (4.3)

38 (1.4)

227 (6.6)

44 (48.4)

31 (30.7)

Esophageal, n(%)

23 (2.3)

-

24 (0.7)

-

1 (1)

Female Genital Tract-Unspecified, n(%)

-

-

9 (0.3)

1 (1.1)

5 (5)

GIST, n(%)

-

-

3 (0.1)

-

-

Gastric, n(%)

17 (1.7)

40 (1.5)

15 (0.4)

-

3 (3)

Head and Neck, n(%)

17 (1.7)

26 (1)

29 (0.8)

-

-

Kidney Cancer, n(%)

47 (4.6)

139 (5.2)

3 (0.1)

-

-

Liver, n(%)

3 (0.3)

4 (0.1)

6 (0.2)

-

-

Lung NSCLC, n(%)

54 (5.3)

16 (0.6)

140 (4.1)

2 (2.2)

3 (3)

Lung SCLC, n(%)

2 (0.2)

-

11 (0.3)

-

-

Lymphoma, n(%)

24 (2.4)

-

-

-

-

Male Genital Organs, n(%)

-

-

-

-

-

Melanoma, n(%)

4 (0.4)

6 (0.2)

14 (0.4)

-

-

Neuroendocrine Tumors, n(%)

2 (0.2)

-

11 (0.3)

-

-

Normal, n(%)

506 (50)

2149 (80.3)*

2149 (62.5)*

-

-

Oncocytoma, n(%)

-

-

-

-

-

Other, n(%)

-

-

12 (0.3)

-

-

Ovarian, n(%)

21 (2.1)

4 (0.1)

23 (0.7)

-

7 (6.9)

Pancreatic, n(%)

21 (2.1)

10 (0.4)

45 (1.3)

-

6 (5.9)

Peritoneum and Retroperitoneum, n(%)

-

-

-

-

-

Prostate, n(%)

64 (6.3)

21 (0.8)

22 (0.6)

-

-

Sarcoma, n(%)

3 (0.3)

6 (0.2)

5 (0.1)

-

-

Small Intestine, n(%)

-

22 (0.8)

5 (0.1)

1 (1.1)

-

Thymus, n(%)

-

2 (0.1)

1 (0)

-

-

Thyroid, n(%)

2 (0.2)

18 (0.7)

2 (0.1)

-

-

Urinary tract cancer, n(%)

1 (0.1)

4 (0.1)

-

-

-

Uterus, n(%)

59 (5.8)

118 (4.4)

38 (1.1)

-

-

Uveal Melanoma, n(%)

-

-

4 (0.1)

-

-

Event Status

Median Time-Till-Event (range), days

-

-

-

208 (79–667)

434 (177–923)

Median Time-Till-Censored (range), days

-

-

-

1055 (55-1095)

1095 (195–1095)

Event, (%)

-

-

-

9 (9.9)

11 (10.9)

Censored, (%)

-

-

-

77 (84.6)

90 (89.1)

Body Mass Index (BMI)

Median BMI (range)

-

-

-

25 (15.8–47.9)

25.8 (17.8–41.3)

Underweight, n(%)

-

-

-

2 (2.2)

1 (1)

Healthy Weight, n(%)

-

-

-

36 (39.6)

43 (42.6)

Overweight, n(%)

-

-

-

21 (23.1)

31 (30.7)

Obesity, n(%)

-

-

-

14 (15.4)

26 (25.7)

Unknown, n(%)

-

-

-

13 (14.3)

-

Death Status

Alive, n(%)

-

-

-

83 (91.2)

95 (94.1)

Dead, n(%)

-

-

-

3 (3.3)

6 (5.9)